BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 18420312)

  • 1. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
    Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
    Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.
    Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H
    Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
    Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
    J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza.
    Deliyannis G; Kedzierska K; Lau YF; Zeng W; Turner SJ; Jackson DC; Brown LE
    Eur J Immunol; 2006 Mar; 36(3):770-8. PubMed ID: 16435281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a CD4 T cell epitope in the pneumonia virus of mice glycoprotein and characterization of its role in protective immunity.
    Claassen EA; van Bleek GM; Rychnavska ZS; de Groot RJ; Hensen EJ; Tijhaar EJ; van Eden W; van der Most RG
    Virology; 2007 Nov; 368(1):17-25. PubMed ID: 17632195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.
    Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z
    Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.
    Wiedig CA; Kramer U; Garbom S; Wolf-Watz H; Autenrieth IB
    Vaccine; 2005 Oct; 23(42):4984-98. PubMed ID: 15985316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation.
    Shi M; Xiang J
    Int Immunol; 2006 Jun; 18(6):887-95. PubMed ID: 16621867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Chibbar R; Wei Y; Liu Q; Xiang J
    Vaccine; 2011 Apr; 29(19):3538-47. PubMed ID: 21406265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.